A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results